FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2361169728> ?p ?o ?g. }

• W2361169728 endingPage "4" @default.
• W2361169728 startingPage "590" @default.
• W2361169728 abstract "To objectively evaluate the clinical efficacy of Gulling Pa'an Capsule (GPC), a Chinese medicine, in treating Parkinson's disease (PD).According to the good clinical practice (GCP) principle, a multi-centered, double-blinded, layered, randomized and grouping-controlled clinical trial was carried out from May 2002 to January 2005 on 242 PD patients. Among them, 53 patients who had never received levodopa were randomized into two groups, 28 in group A treated with GPC, and 25 in group B treated with placebo; patients who had received levodopa were assigned depending on the Hoehn & Yahr (H-Y) grade, to 4 groups, 75 and 19 of grade 1.5 -3 in group C and E, respectively, 79 and 16 of grade 4 in group D and F, respectively, patients in group C and E were treated with GPC and Levodopa, and those in group D and F treated with placebo and Levodopa for control. The treatment course was 12 weeks for all. Changes of unified Parkinson's disease rating scale (UPDRS) II/III scores in comparing with the baseline were assessed. For the groups C, D, E and F, the dosage of levodopa administered was also recorded. Meanwhile, the blood pressure, pulse rate, blood and urine routine, liver and renal functions, electrocardiogram (ECG) and adverse reactions were monitored as the indices for safety supervise.(1) After treatment, symptoms were markedly improved in 1 out of the 28 patients in group A and improved in 11, the markedly improving rate was 3.6% and the improving rate 39.3%; while in group B, the corresponding outcomes were 0 (0/25) and 28.0% (7/25) respectively, showing insignificant difference between the two groups. UPDRS scores, including the total, II and III scores were all significantly lowered in group A after treatment (P < 0.01, P < 0.05); while in group B, significant lowering only showed in terms of UPDRS III (P < 0.05); but the inter-group comparison of the changes in all the three items showed no significant difference. (2) The significant improving rate was 12.0% (9/75) and improving rate 48.0% (36/75) in group C, while those in group D, 12.7% (10/79) and 24.1% (19/79) respectively, the efficacy in group C was better (P < 0.05). The items of 3 UPDRS scores in groups C and D were all significantly lowered after treatment (P < 0.01), and the lowering in group C was more significant in terms of the total and II scores (P < 0.05). (3) The significant improving rate was 5.3% (1/19) and improving rate 36.8% (7/19) in group E, while in group F 0% (0/19) and 25.0% (4/16), respectively, showing insignificant difference between them; UPDRS scores lowered significantly in the two groups after treatment (P < 0.01), also showed no statistical significance in comparison (P > 0.05). (4) The dosage of Levodopa required in groups C and E was significantly reduced after treatment (P < 0.05), while in groups D and F, it was unchanged (P > 0.05); yet, the further analysis displayed that significant reduction only presented in group C (P < 0.05), not in the other three groups.The overall efficacy of levodopa in combined with GPC for treating PD patients of H-Y grade 1.5 -3 is significantly higher than that of levodopa alone. GPC shows obvious effects in improving patients' motor syndrome and the quality of life; as used in combining with levodopa, the dosage of levodopa required could be reduced." @default.
• W2361169728 created "2016-06-24" @default.
• W2361169728 creator A5015894942 @default.
• W2361169728 creator A5042562433 @default.
• W2361169728 creator A5066935433 @default.
• W2361169728 date "2009-07-01" @default.
• W2361169728 modified "2023-09-25" @default.
• W2361169728 title "[A multi-centered randomized double-blinded controlled clinical study on efficacy of gulling pa'an capsule in treating Parkinson's disease]." @default.
• W2361169728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19852288" @default.
• W2361169728 hasPublicationYear "2009" @default.
• W2361169728 type Work @default.
• W2361169728 sameAs 2361169728 @default.
• W2361169728 citedByCount "2" @default.
• W2361169728 countsByYear W23611697282012 @default.
• W2361169728 countsByYear W23611697282015 @default.
• W2361169728 crossrefType "journal-article" @default.
• W2361169728 hasAuthorship W2361169728A5015894942 @default.
• W2361169728 hasAuthorship W2361169728A5042562433 @default.
• W2361169728 hasAuthorship W2361169728A5066935433 @default.
• W2361169728 hasConcept C126322002 @default.
• W2361169728 hasConcept C141071460 @default.
• W2361169728 hasConcept C142724271 @default.
• W2361169728 hasConcept C168563851 @default.
• W2361169728 hasConcept C197934379 @default.
• W2361169728 hasConcept C204787440 @default.
• W2361169728 hasConcept C27081682 @default.
• W2361169728 hasConcept C2778778583 @default.
• W2361169728 hasConcept C2779134260 @default.
• W2361169728 hasConcept C2779734285 @default.
• W2361169728 hasConcept C2780304432 @default.
• W2361169728 hasConcept C2992053201 @default.
• W2361169728 hasConcept C535046627 @default.
• W2361169728 hasConcept C59822182 @default.
• W2361169728 hasConcept C71924100 @default.
• W2361169728 hasConcept C86803240 @default.
• W2361169728 hasConcept C90924648 @default.
• W2361169728 hasConceptScore W2361169728C126322002 @default.
• W2361169728 hasConceptScore W2361169728C141071460 @default.
• W2361169728 hasConceptScore W2361169728C142724271 @default.
• W2361169728 hasConceptScore W2361169728C168563851 @default.
• W2361169728 hasConceptScore W2361169728C197934379 @default.
• W2361169728 hasConceptScore W2361169728C204787440 @default.
• W2361169728 hasConceptScore W2361169728C27081682 @default.
• W2361169728 hasConceptScore W2361169728C2778778583 @default.
• W2361169728 hasConceptScore W2361169728C2779134260 @default.
• W2361169728 hasConceptScore W2361169728C2779734285 @default.
• W2361169728 hasConceptScore W2361169728C2780304432 @default.
• W2361169728 hasConceptScore W2361169728C2992053201 @default.
• W2361169728 hasConceptScore W2361169728C535046627 @default.
• W2361169728 hasConceptScore W2361169728C59822182 @default.
• W2361169728 hasConceptScore W2361169728C71924100 @default.
• W2361169728 hasConceptScore W2361169728C86803240 @default.
• W2361169728 hasConceptScore W2361169728C90924648 @default.
• W2361169728 hasIssue "7" @default.
• W2361169728 hasLocation W23611697281 @default.
• W2361169728 hasOpenAccess W2361169728 @default.
• W2361169728 hasPrimaryLocation W23611697281 @default.
• W2361169728 hasRelatedWork W2016205410 @default.
• W2361169728 hasRelatedWork W2038427634 @default.
• W2361169728 hasRelatedWork W2074112508 @default.
• W2361169728 hasRelatedWork W2085830368 @default.
• W2361169728 hasRelatedWork W2361169728 @default.
• W2361169728 hasRelatedWork W2363563670 @default.
• W2361169728 hasRelatedWork W2389819105 @default.
• W2361169728 hasRelatedWork W3031672753 @default.
• W2361169728 hasRelatedWork W4226161652 @default.
• W2361169728 hasRelatedWork W4288748910 @default.
• W2361169728 hasVolume "29" @default.
• W2361169728 isParatext "false" @default.
• W2361169728 isRetracted "false" @default.
• W2361169728 magId "2361169728" @default.
• W2361169728 workType "article" @default.